IMS Health has made its third cloud-based acquisition in as many months, snapping up mobile sales and marketing systems provider 360 Vantage. The deal continues IMS' whirlwind push into the cloud that has also seen it snag Appature and Semantelli in the past few months.
Guilin Pharmaceuticals has advanced a system to combat use of fake antimalarial drugs. The Chinese drugmaker has launched an SMS-based system for patients in Africa to check whether their antimalarial meds are the real thing.
Investors have activated a new "crowdfunding" website for life sciences deals. Dubbed VentureHealth, the website aims to expand the number of deep-pocketed players who are actively investing in medical technology startups as some traditional sources wilt.
Pfizer is testing the online-sales waters with a new program to sell Viagra directly to consumers.
In a new stab at improving online searches for clinical trials, a nonprofit effort has brought the world an open-source site called MyClinicalTrialLocator.com. The website was designed to make searches easier for patients and serve as a resource to the global research community.
Two of my senior colleagues and I are headed to Boston this week for the Bio-IT World Expo in Boston. I'll be posting breaking news from the show as well as interviews with some of the top minds in bioinformatics, clinical IT and discovery software.
Cloud computing isn't anything new in the pharma world, where drugmakers have used web-based storage, software and services for years. But from the looks of a recent Bio-IT World survey of 121 senior execs in life sciences, cloud computing has become pervasive in pharma organizations.
Mobile has gone mainstream in the biopharma industry, at least for those who work as tablet-toting sales reps or other jobs that take them away from the office. Read more >>
Like a good tech partner should, NextDocs has stuck close to Microsoft and its software platforms for years.
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.